Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.86 |
| ▸ | USP2 | O75604 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | DRD1 | P21728 | 1/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248559 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL29523079 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL248270 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL29355814 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Eprinomectin SCHEMBL29392105 | 0.99 | HSPD1 (0.98) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Eprinomectin SCHEMBL120548 | 0.99 | HSPD1 (0.98) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Propylene Glycol SCHEMBL9901967 | 0.97 | HSPD1 (0.94) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL13309158 | 0.96 | HSPD1 (0.93) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL19708888 | 0.96 | HSPD1 (0.91) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL3913613 | 0.96 | HSPD1 (0.91) | HSPD1HSPE1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355724-A1 | ANTHELMINTHIC MACROLIDE SYNTHESIS | NORBROOK LABORATORIES LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355724-A1 | ANTHELMINTHIC MACROLIDE SYNTHESIS | ABAT, EEF1A2, EEF2 | HSPD1 1170/4885HSPE1 2174/4885MEN1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.